Sign In
Buy TRML
$47.98
+0 (+0%)
At Close: Jan 27, 2026
Novartis completes acquisition of Tourmaline Bio
09:52am, Tuesday, 28'th Oct 2025
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of comm
Novartis announces expiration of Tourmaline Bio tender offer
02:25am, Tuesday, 28'th Oct 2025
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiar
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
01:00am, Wednesday, 22'nd Oct 2025
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection w
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Novartis announces commencement of tender offer to acquire Tourmaline Bio
07:44am, Monday, 29'th Sep 2025
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)
05:30pm, Monday, 15'th Sep 2025
NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders an
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
12:11pm, Wednesday, 10'th Sep 2025
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
This Small Biotech Stock Is Surging Today. Here's Why.
12:35pm, Tuesday, 09'th Sep 2025
Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is
Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal
06:44am, Tuesday, 09'th Sep 2025
Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highligh
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders
05:41am, Tuesday, 09'th Sep 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Tourmaline Bio, Inc. (NASDAQ: TRML) to Novartis AG for $48.00 per share in cash is fair t
Novartis strikes $1.4bn deal for Tourmaline Bio
03:02am, Tuesday, 09'th Sep 2025
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. The
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders
02:43am, Tuesday, 09'th Sep 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Tourmaline (NASDAQ: TRML) for possible breaches of fiduciary duty and other violations of law in its transaction with a Novartis. Click here
Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal
02:02am, Tuesday, 09'th Sep 2025
The deal will boost the Swiss pharmaceutical company's cardiovascular drug pipeline.
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
01:15am, Tuesday, 09'th Sep 2025
Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday.
